Clover Health Investments, Corp. - Class A Common stock (CLOV)
Financial Services › Hospital & Medical Service Plans
Price History
Feb 9, 2026 — Aug 20, 2026Investment Snapshot
- Trading 489% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 5.4% — below-average profitability
- Revenue growing at 40% annually
Clover Health Investments, Corp. - Class A Common stock (CLOV) is a Financial Services company operating in Hospital & Medical Service Plans, listed on the NASDAQ , with a market capitalisation of $2.4 billion . Key value metrics: P/E ratio 120.0, P/B ratio 6.50, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Clover Health Investments, Corp. - Class A Common stock — Fundamental Analysis Summary
Clover Health Investments, Corp. - Class A Common stock (CLOV) is currently trading 489% above its Graham Number of $0.79, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 120.0x.
On financial health, CLOV shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and modest return on equity of 5.4% (sector average: 5.4%), and manageable leverage with a debt-to-equity ratio of 0.72.
StockPik's composite Value Score for CLOV is 31/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CLOV reports a thin gross margin of 14.6% (sector average: 16.7%) and a modest operating margin of 0.8%.
CLOV shows revenue growing at 40% year-over-year, with earnings declining at 99%.